Rilexine 75 mg Tablets for dogs and cats

Страна: Ірландія

мова: англійська

Джерело: HPRA (Health Products Regulatory Authority)

Активний інгредієнт:

Cefalexin monohydrate

Доступна з:

Virbac S.A.

Код атс:

QJ01DB01

ІПН (Міжнародна Ім'я):

Cefalexin monohydrate

Дозування:

75 mg/tablet

Фармацевтична форма:

Tablet

Тип рецепту:

POM: Prescription Only Medicine as defined in relevant national legislation

Терапевтична група:

Cats, Dogs

Терапевтична области:

cefalexin

Терапевтичні свідчення:

Antibacterial

Статус Авторизація:

Authorised

Дата Авторизація:

1988-10-01

Характеристики продукта

Health Products Regulatory Authority
19 January 2022
CRN00CHP7
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Rilexine 75 mg Tablets for dogs and cats
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One tablet contains:
ACTIVE SUBSTANCE:
Cefalexin
75mg
(as Cefalexin Monohydrate)
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablets.
Creamy oblong tablet with small brown spots marked with a score line.
The tablets can be divided into halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and cats
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of bacterial skin infections in dogs (including deep
and superficial pyodermas) caused by organisms
susceptible to Cefalexin.
For the treatment of cutaneous and subcutaneous infections (wounds and
abscesses) in cats caused by organisms susceptible
to Cefalexin.
For the treatment of urinary-tract infections in cats and dogs
(including nephritis and cystitis) caused by organisms susceptible
to Cefalexin.
4.3 CONTRAINDICATIONS
Do not use in animals which are known to be hypersensitive to
penicillins and cephalosporins.
Do not use in rabbits, guinea pigs, hamsters and gerbils.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
As with other antibiotics which are excreted mainly by the kidneys,
unnecessary accumulation may occur in the body when
renal function is impaired. In case of known renal insufficiency, the
dose should be reduced and antimicrobials known to be
nephrotoxic should not be administered concurrently.
This product should not be used to treat puppies of less than 1 kg of
bodyweight or kittens under 9 weeks of age.
Health Products Regulatory Authority
19 January 2022
CRN00CHP7
Page 2 of 5
Use of the product deviating from the instructions given in the SPC
may increase the prevalence of bacteria resistant to
Cefalexin and may decrease the effectiveness of treatment with other
cephalosporins and penicillins,